Femasys (FEMY) Consolidated Net Income (2020 - 2026)
Femasys' (FEMY) quarterly Consolidated Net Income came in at -$4.5 million in Q2 2026, up 2.55% on a YoY basis from -$4.4 million in Q2 2025, and up 2.55% quarter-over-quarter from -$4.6 million in Q2 2025.
Analysis
Femasys (FEMY) Consolidated Net Income (2020 - 2026) Analysis & Trends
Femasys (FEMY) has reported Consolidated Net Income for 7 consecutive years, with -$4.5 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Consolidated Net Income rose 2.55% year-over-year to -$4.5 million; the trailing twelve-month figure through Jun 2026 stood at -$20.1 million (up 4.47% YoY), and the FY2025 full-year result was -$14.7 million, up 21.8% from the prior year.
- Consolidated Net Income grew to -$4.5 million in Q2 2026 per FEMY's latest filing, from -$4.6 million in the prior quarter.
- Across five years, Consolidated Net Income topped out at -$2.6 million in Q2 2022 and bottomed at -$5.9 million in Q1 2025.
- Historically, Consolidated Net Income has averaged -$4.0 million across 5 years, with a median of -$4.0 million in 2023.
- The sharpest annual moves came in 2022 and 2026: Consolidated Net Income plunged 143.21% in 2022, then increased 2.55% in 2026.
- Over 5 years, Consolidated Net Income stood at -$2.9 million in 2022, then plunged by 52.84% to -$4.4 million in 2023, then fell by 16.17% to -$5.1 million in 2024, then rose by 10.5% to -$4.6 million in 2025, then gained by 2.55% to -$4.5 million in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$4.5 million, -$4.6 million, and -$5.9 million for Q2 2026, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 905.00 Mn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | -92.00 Mn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Femasys | 9.37 Mn | 7.92 Mn | 189,391.00 | -4.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.47 Mn |
| Jun 30, 2025 | -4.59 Mn |
| Mar 31, 2025 | -5.90 Mn |
| Dec 31, 2024 | -5.12 Mn |
| Sep 30, 2024 | -5.41 Mn |
| Jun 30, 2024 | -4.68 Mn |
| Mar 31, 2024 | -3.60 Mn |
| Dec 31, 2023 | -4.41 Mn |
| Sep 30, 2023 | -4.00 Mn |
| Jun 30, 2023 | -2.89 Mn |
| Mar 31, 2023 | -2.95 Mn |
| Dec 31, 2022 | -2.89 Mn |
| Sep 30, 2022 | -2.98 Mn |
| Jun 30, 2022 | -2.63 Mn |
| Mar 31, 2022 | -2.88 Mn |
| Dec 31, 2021 | -2.36 Mn |
| Sep 30, 2021 | -2.26 Mn |
| Jun 30, 2021 | -1.08 Mn |
| Mar 31, 2021 | -1.83 Mn |
| Dec 31, 2020 | -1.66 Mn |